Investigational drug · Phase 2
QD202
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: May 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "QD202"
First trial start
2025
Oct 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QD202", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "QD202" as an intervention, largest first.
- Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular ThrombectomyPivotal-lookingRecruiting
Shanghai QuietD Biotechnology Co., Ltd.Industry
NCT07581210 · 120 participants (planned) · Start Oct 14, 2025 · Primary completion Aug 2026
Drug: QD202; Placebo · For: Acute Ischemic Stroke
Sites: Meizhou, China; Luoyang, China; Nanyang, China · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.